Ade is a version of the French friendly farewell adieu but ADE is also the acronym for the rather unfriendly Antibody-Dependent Enhancement (ADE) and it's not a conspiracy theory. Alas.
It's an uncanny machanism of the immune system, which basically means that disease due to infection after vaccination is worse than disease caused by infection without prior vaccination, for some patients. If the second infection is with a different variant of the virus than the variant/ wild-type the vaccine is based on.
Nobel laureate, Luc Montagnier, discoverer of the HI virus, mentioned ADE as a major complication that will kill many vaccinees when they get reinfected with new variants of SARS-CoV-2.
ADE was first discovered with dengue virus infections.
A reinfection with dengue virus makes the clinical symptoms worse and heightens the risk of devoloping severe dengue fever. So ADE is a immunological phenomenon which can even happen without vaccinations.
ADE in dengue infections
A useful introduction to ADE in general can be found on wikipedia.
http://bit.ly/ADE_introduction
In May 2016 poster presentation in the Journal of Viral Eradication the authors suggested that antibodies against the spike protein of SARS-CoV may cause ADE and the authors were concerned about the use of a SARS-CoV vaccine.¹ A 2016 conclusion that should ring the alarm bells 2021.
1)Chun-Sheng Yeh, Jyh-Yuan Yang, Wu-Tse Liu, Jason C. Huang, Yi-Ming Arthur Chen, Sheng-Fan Wang,
P84 - SARS coronavirus has antibody-dependent enhancement (ADE) effect through the autologous antibodies against envelope spikes on Fcγ receptor expressing cells,
Journal of Virus Eradication,Volume 2, Supplement 1,2016,Page 48,ISSN 2055-6640,https://doi.org/10.1016/S2055-6640(20)31216-4.
(https://www.sciencedirect.com/science/article/pii/S2055664020312164)
SARS coronavirus has antibody-dependent enhancement (ADE) effect through the autologous antibodies against envelope spikes on Fcγ receptor expressing cells
The mRNA B-cell vaccine attack on the Mighty Corona may go either way. The game is still undecided.
"...two different ADE risks have possible implications for SARS-CoV-2 B-cell vaccines for subsets of populations based on age, cross-reactive antibodies, variabilities in antibody levels over time, and pregnancy. These models place increased emphasis on the importance of developing safe SARS-CoV-2 T-cell vaccines that are not dependent upon antibodies."²
2)Ricke DO. Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies. Front Immunol. 2021 Feb 24;12:640093. doi: 10.3389/fimmu.2021.640093. PMID: 33717193; PMCID: PMC7943455.
Click below to read the paper:
Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies.
In a paper published October 28 2020 in the International Journal of Clinical Practice the authors came to this sobering conclusion:
"Based on the published literature, it should have been obvious to any skilled medical practitioner in 2019 that there is a significant risk to vaccine research subjects that they may experience severe disease once vaccinated, while they might only have experienced a mild, self-limited disease if not vaccinated"³
Back then this concerned only vaccine research subjects, but nowadays this pertains to all vaccinees.
3) Cardozo T, Veazey R. Informed consent disclosure to vaccine trial subjects of risk of COVID-19 vaccines worsening clinical disease. Int J Clin Pract. 2021 Mar;75(3):e13795. doi: 10.1111/ijcp.13795. Epub 2020 Dec 4. PMID: 33113270; PMCID: PMC7645850.
Here is the link to the paper:
Informed consent disclosure to vaccine trial subjects of risk of COVID-19 vaccines worsening clinical disease.
Further reading:
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
Swiss Medical Weekly - Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?
A perspective on potential antibody-dependent enhancement of SARS-CoV-2
Why ADE Hasn't Been a Problem With COVID Vaccines | MedPage Today / 2021 03 16
